Integrating patient-reported outcomes into clinical trials might provide a viewpoint on the influence of CD44-targeted nanocarriers on people receiving NSCLC medication, guaranteeing that progress in treatment leads to significant enhancements in patients’ well-being. This evidence concerns the gene CD44 and non-small cell lung carcinoma.